finasteride
AssetAlso UROCOM-R1, MK-906, NSC-741485, NSC-759318
Inhibits 5-alpha-reductase, reducing dihydrotestosterone production and prostate enlargement.
- Stage
- Approved
- Modality
- Small molecule
- Target
- SRD5A2
- 3
- Indications
- 1
- Trial
- 2
- Developers
Indications
3Androgenetic alopecia
Approved, hitnews.co.kr, 8 Oct 2026
Male pattern baldness
Approved, koreabiomed.com, 8 Oct 2026
Benign prostatic hyperplasia
Phase 3, Not yet recruiting, NCT07870759, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials1
- Evidence for its targets2
- Competitors5
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.